Cite
HARVARD Citation
Elewski, B. et al. (n.d.). AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis. Annals of the rheumatic diseases. pp. 1319-1320. [Online].